Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could blood thinners stop a second stroke? new trial investigates

NCT ID NCT06486792

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at people over 65 who recently had a stroke with no clear cause. Doctors suspect they may have hidden atrial fibrillation (an irregular heartbeat) not caught in the hospital. The trial compares two treatments: a blood thinner (apixaban) or aspirin, to see which better prevents another stroke or blood clots. About 1,148 participants will be monitored for up to 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Apixaban (a blood thinner) or aspirin
What this could lead to
If successful, this could show that using blood thinners early after a stroke of unknown cause reduces the risk of another stroke.
What could go wrong
This is a Phase 4 trial, but the benefit-risk balance of blood thinners versus aspirin in this specific group is still unproven. Blood thinners carry a risk of bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 1,148 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Included patients must fulfill the following 4 criteria: 1. patient aged ≥65 years with: 1. recent (\<15 days) cerebral infarction 2. with cerebral ischemia proven on MRI or head-CT 2. with no known atrial fibrillation before stroke and no atrial fibrillation detected during hospital stay (monitoring or telemetry) and no mural thrombus. 3. but with suspected atrial fibrillation: 1. multiple territorial (i.e., in the territory of a cerebral artery or one of its branches) cerebral infarctions in several arterial territories involving both hemispheres, or in the same hemisphere, or in both anterior and posterior circulation, symptomatic or not 2. or a single cerebral infarction and systemic emboli (e.g., renal, splenic, hepatic or mesenteric infarction, peripheral emboli in arm or leg), symptomatic or not 3. or any ischemic stroke with dilation of atrium (\>34 mL/m²) or left atrial spontaneous echocardiographic contrast or LAA velocities \< 40 cm/sec or pro BNP \> 400 pg/mL or left ventricular ejection fraction (LVEF) \< 40% or supraventricular extrasystole ≥ 400/24 h or longest "atrial run" ≥ 20 beats on telemetry 4. or age ≥80 year-old and a single infarction 4. and a plan to detect atrial fibrillation with, long term Holter ECG, wearing device or implantable loop recorder 5. with a Rankin score equal or less than 4 6. patient has signed an informed consent 7. Patient is affiliated to a social security. Exclusion Criteria: 1. Patients with a known cause of stroke, using ASCOD classification A1, C1, S1, O1, D1 2. Symptomatic brain hemorrhage (the mere presence of microbleeds on gradient echo imaging is not an exclusion criteria) 3. Uncontrolled hypertension (following the judgment of the investigator) 4. Clear indication to anticoagulant or antiplatelet therapy 5. Contra-indication to anticoagulant or antiplatelet therapy 6. Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits 7. Participation in another interventional clinical trial. 8. Under contraception in case of childbearing potential 9. Patient under guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bichat Hospital

    RECRUITING

    Paris, Paris, 75018, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.